Key result
Low-dose aspirin for primary prevention of cardiovascular disease and cancer in the general US population aged 40 to 85 years yielded a positive benefit-harm index ranging from 2 to 8 net prevented events per 1,000 persons over 10 years.
Why the study?
Does low dose aspirin improve the benefit-harm balance for primary prevention of cardiovascular disease and cancer in a general US population between 40 and 85 years of age?
Does low dose aspirin improve the benefit-harm balance for primary prevention of cardiovascular disease and cancer in a general US population between 40 and 85 years of age?
A quantitative benefit-harm analysis suggests that the overall benefits of low-dose aspirin for primary prevention of cardiovascular disease and cancer outweigh the harms (gastrointestinal bleeding and hemorrhagic stroke) in the general US population aged 40 to 85.
Supports aspirin consideration for primary prevention in adults 40-85; extends prior trials with US population-level net benefit quantification.
Aspirin is widely used for prevention of cardiovascular disease. In recent years randomized trials also suggested a preventive effect for various types of cancer. We aimed to assess, in a quantitative way, benefits and harms of aspirin for primary prevention of both cardiovascular disease and cancer for a general US population between 40 and 85 years of age.
No takes yet. Share an insight, caveat, or question.
Stegeman et al. (2015) studied Primary prevention of cardiovascular disease and cancer. Aspirin vs. No aspirin was evaluated on Benefit-harm index (prevented benefit events minus excess harm events over 10 years per 1,000 persons). Low-dose aspirin for primary prevention of cardiovascular disease and cancer in the general US population aged 40 to 85 years yielded a positive benefit-harm index ranging from 2 to 8 net prevented events per 1,000 persons over 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: